Immunoglobulin E specific for Atriplex wrightii pollen allergens (sIgE (Atriplex wrightii))

Immunoglobulin E (IgE) antibodies specific for Atriplex wrightii pollen allergens are the primary mediators of allergic sensitization to Wright's saltbush, a common weed in arid and semi-arid regions (USDA Plants Database). These antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (NIH/NIAID). Upon subsequent exposure to Atriplex wrightii pollen, the allergens cross-link the surface-bound IgE, triggering the degranulation of these effector cells and the release of inflammatory mediators such as histamine (StatPearls). This process leads to the clinical manifestations of seasonal allergic rhinitis, conjunctivitis, and allergic asthma. Therapeutic targeting of this pathway involves the use of anti-IgE monoclonal antibodies like Omalizumab, which bind to the Fc region of circulating IgE to prevent its interaction with receptors (NCBI/StatPearls). Furthermore, allergen-specific immunotherapy (AIT) utilizes extracts of Atriplex wrightii pollen to induce immunological tolerance, shifting the immune response away from IgE production toward protective IgG4 antibodies (AAAAI).

Other names

Wright's saltbush specific IgEAtriplex wrightii sIgEAnti-Atriplex wrightii IgEIgE anti-Atriplex wrightii

Neutralization of circulating IgE to prevent binding to high-affinity FcεRI receptors on mast cells and basophils, and induction of immune tolerance through allergen-specific immunotherapy.